Single-Step, High-Efficiency CRISPR-Cas9 Genome Editing in Primary Human Disease-Derived Fibroblasts
Matteo Martufi(Age UK), Klio Maratou(GlaxoSmithKline (United Kingdom))
Cited by 26
Related Papers
<i>In silico</i>and<i>in vitro</i>evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization
|Nucleic Acids Research|2015|109
Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs
|Molecular Therapy — Nucleic Acids|2017|62
Single step, high efficiency CRISPR-Cas9 genome editing in primary human disease-derived fibroblasts
|bioRxiv (Cold Spring Harbor Laboratory)|2018|3